1-7 of 7
Christine Lui
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Three-year follow-up analysis of axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma (ZUMA-5)

Clinical Trials & Observations
Sattva S. Neelapu, Julio C. Chavez, Alison R. Sehgal, Narendranath Epperla, Matthew Ulrickson, Emmanuel Bachy, Pashna N. Munshi, Carla Casulo, David G. Maloney, Sven de Vos, Ran Reshef, Lori A. Leslie, Olalekan O. Oluwole, Ibrahim Yakoub-Agha, Rashmi Khanal, Joseph Rosenblatt, Ronald Korn, Weixin Peng, Christine Lui, Jacob Wulff, Rhine Shen, Soumya Poddar, A. Scott Jung, Harry Miao, Sara Beygi, Caron A. Jacobson
Journal: Blood
Blood (2024) 143 (6): 496–506.
https://doi.org/10.1182/blood.2023021243
Published: 2024
Includes: Supplemental data
Journal Articles

3-Year Analysis of ZUMA-12: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) As First-Line Therapy in Patients with High-Risk Large B-Cell Lymphoma (LBCL)

Julio C. Chavez, Michael Dickinson, Javier L. Munoz, Matthew L. Ulrickson, Catherine Thieblemont, Olalekan O. Oluwole, Alex F. Herrera, Chaitra S Ujjani, Yi Lin, Peter A. Riedell, Natasha K. Kekre, Sven de Vos, Christine Lui, Jacob Wulff, Chad M. Williams, Weixin Peng, Ioana Kloos, Hairong Xu, Sattva S. Neelapu
Journal: Blood
Blood (2023) 142 (Supplement 1): 894.
https://doi.org/10.1182/blood-2023-174510
Published: 2023
Journal Articles

A Retrospective Intra-Patient Analysis from ZUMA-5: Axicabtagene Ciloleucel (Axi-Cel) Compared with Prior Standard-of-Care Therapy in Patients with Relapsed/Refractory Follicular Lymphoma

Emmanuel Bachy, Sattva S. Neelapu, Julio C. Chavez, Ibrahim Yakoub-Agha, Christine Lui, Jacob Wulff, Harry Miao, Olga Nikolajeva, Timothy Best, Camille Linot, Caron A. Jacobson
Journal: Blood
Blood (2023) 142 (Supplement 1): 4865.
https://doi.org/10.1182/blood-2023-175055
Published: 2023
Journal Articles

Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma: 4-Year Follow-up from the Phase 2 ZUMA-5 Trial

Sattva S. Neelapu, Julio C. Chavez, Alison R Sehgal, Narendranath Epperla, Matthew L. Ulrickson, Emmanuel Bachy, Pashna N. Munshi, Carla Casulo, David G Maloney, Sven de Vos, Ran Reshef, Lori A. Leslie, Olalekan O. Oluwole, Ibrahim Yakoub-Agha, Rashmi Khanal, Joseph D. Rosenblatt, Weixin Peng, Christine Lui, Jacob Wulff, Rhine R. Shen, Soumya Poddar, Andrew Lee, Harry Miao, Olga Nikolajeva, Caron A. Jacobson
Journal: Blood
Blood (2023) 142 (Supplement 1): 4868.
https://doi.org/10.1182/blood-2023-174914
Published: 2023
Journal Articles

3-Year Follow-up Analysis of ZUMA-5: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL)

Sattva S. Neelapu, Julio Chavez, Alison R. Sehgal, Narendranath Epperla, Matthew Ulrickson, Emanuel Bachy, Pashna N. Munshi, Carla Casulo, David G. Maloney, Sven de Vos, Ran Reshef, Lori A. Leslie, Olalekan O. Oluwole, Ibrahim Yakoub-Agha, Rashmi Khanal, Joseph D. Rosenblatt, Jiali Yan, Qinghua Song, Weixin Peng, Christine Lui, Jacob Wulff, Rhine R. Shen, Soumya Poddar, Harry Miao, Sara Beygi, Caron A. Jacobson
Journal: Blood
Blood (2022) 140 (Supplement 1): 10380–10383.
https://doi.org/10.1182/blood-2022-156120
Published: 2022
Journal Articles

Long-Term Follow-up Analysis of ZUMA-5: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL)

Sattva S. Neelapu, Julio C. Chavez, Alison R. Sehgal, Narendranath Epperla, Matthew L. Ulrickson, Emmanuel Bachy, Pashna N. Munshi, Carla Casulo, David G. Maloney, Sven de Vos, Ran Reshef, Lori A. Leslie, Olalekan O. Oluwole, Ibrahim Yakoub-Agha, Rashmi Khanal, Joseph D. Rosenblatt, Marika Sherman, Jinghui Dong, Alessandro Giovanetti, Yin Yang, Christine Lui, Zahid Bashir, A Scott Jung, Caron Jacobson
Journal: Blood
Blood (2021) 138 (Supplement 1): 93.
https://doi.org/10.1182/blood-2021-148473
Published: 2021
Journal Articles

Primary Analysis of ZUMA-12: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) As First-Line Therapy in Patients with High-Risk Large B-Cell Lymphoma (LBCL)

Sattva S. Neelapu, Michael Dickinson, Javier Munoz, Matthew L. Ulrickson, Catherine Thieblemont, Olalekan O. Oluwole, Alex F. Herrera, Chaitra S. Ujjani, Yi Lin, Peter A. Riedell, Natasha Kekre, Sven de Vos, Christine Lui, Francesca Milletti, Jinghui Dong, Hairong Xu, Julio C. Chavez
Journal: Blood
Blood (2021) 138 (Supplement 1): 739.
https://doi.org/10.1182/blood-2021-148009
Published: 2021